二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： (一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用); (三) 中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定; （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 ( 离 ) 休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定〈如 适用); （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见》的相关规定（如适用）; 独立董事候选人声明与承诺 本人谢获宝,已充分了解并同意由提名人广州金域医学检验集团股份有限公 司董事会提名为广州金域医学检验集团股份有限公司第四届董事会独立董事候 选人。本人公开声明，本人具备独立董事任职资格,保证不存在任何影响本人担 任广州金域医学检验集团股份有限公司独立董事独立性的关系,具体声明并承诺 如下: 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-061 广州金域医学检验集团股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第二次临时股东大会 召开的日期时间：2024 年 9 月 27 日 14 点 30 分 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 27 日 至 2024 年 9 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大会召 ...

请务必阅读正文之后的免责声明及其项下所有内容 金域医学（603882.SH） 优于大市 二季度营收环比增长 11%，三级医院收入占比快速提升 二季度营收环比增长 11%，信用减值损失影响表观业绩。2024 年上半年公司 实现营收 38.81 亿（-9.9%），归母净利润 0.90 亿（-68.53%），扣非归母 净利润 0.74 亿（-72.8%）。业绩表观大幅下滑主要是由于常规检测需求增 长速度不及预期，固定成本投入较高，导致规模效应不及预期，另外由于部 分应收账款回款周期较长，导致对应的信用减值损失金额较大。单二季度实 现营收 20.40 亿（-6.9%），环比增长 10.8%；归母净利润 1.08 亿，环比 24Q1 大幅改善。 高端技术平台和三级医院收入占比双双提升，创新项目高速放量。2024 年上 半年公司高端技术平台收入占比达 54.0%（+1.0pp），三级医院收入占比近 45.8%（+5.8pp），公司通过与一批顶级三级医院达成产学研全面合作，深 入推广区域检验中心共建服务模式，进一步夯实"顶天立地"的业务格局。 公司持续发挥以临床与疾病为导向的产品和技术优势，上半年感染 tNGS 系 列、呼 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-055 广州金域医学检验集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2024 年 9 月 13 日中午 12:00 前访问网址 h ttps://eseb.cn/1hzIJbOqWg8 进行会前提问，或将相关问题通过电子邮件 的形式发送至公司董事会办公室邮箱：sid@kingmed.com.cn。本公司将在 业绩说明会上对投资者普遍关注的问题进行统一回答。 广州金域医学检验集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 31 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公 司 2024 年半年度的经营成果、财务状况，公司计划于 2024 年 9 月 14 日 15:00-16:00 举行 2024 年半年度业绩说明会（以下简称"业绩说明会"），就投 资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络文字互 ...

2024 年 09 月 01 日 评级 买入 | --- | --- | |-----------------------|-------------| | 当前价格（元） | 27.51 | | 52 周价格区间（元） | 25.01-68.64 | | 总市值（百万） | 12895.90 | | 流通市值（百万） | 12809.97 | | 总股本（万股） | 46877.20 | | 流通股（万股） | 46564.80 | | | | 涨跌幅比较 金域医学 医疗服务 -57% -37% -17% 3% 23% | --- | --- | --- | --- | |-------------------|---------|---------|--------| | 2023-09 2023-12 | 2024-03 | 2024-06 | | | % | 1M | 3M | 12M | | 金域医学 | 3.89 | -18.78 | -55.46 | | | | | | 医疗服务 -1.60 -12.71 -45.43 吴号 分析师 执业证书编号: S0530522050003 wuhao58@ ...

证券研究报告 非金融公司|公司点评|金域医学（603882） 信用减值影响业绩，盈利能力环比改善 请务必阅读报告末页的重要声明 glzqdatemark1 2024年09月05日 证券研究报告 |报告要点 公司发布 2024 年半年报。2024 年上半年实现收入 38.81 亿元，同比下降 9.92%；归母净利润 8965.02 万元，同比下降 68.53%；扣非归母净利润 7424.94 万元，同比下降 72.76%。单二季 度实现收入 20.40 亿元，同比下降 6.91%；归母净利润 1.08 亿元，同比下降 19.92%；扣非归 母净利润 1.04 亿元，同比下降 21.54%。 |分析师及联系人 郑薇 许津华 SAC：S0590521070002 SAC：S0590523070004 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年09月05日 金域医学(603882) 信用减值影响业绩，盈利能力环比改善 | --- | --- | |----------------------------|-------------------| | | | ...

Investment Rating - The report maintains a "Recommend" rating for the company [6] Core Views - The company's profitability rebounded in Q2 2024, with a significant improvement in operating conditions compared to Q1 2024 [1] - Revenue growth is expected to turn positive starting from Q3 2024, driven by lower growth base, industry consolidation, and optimized competitive landscape [1] - The impact of credit impairment provisions on the company's performance is expected to gradually diminish [1] - The company is leveraging technological innovation and digital transformation to enhance efficiency and quality, with 92 new projects launched in H1 2024 and over 4,000 testing items available [2] Financial Performance - In H1 2024, the company reported revenue of RMB 3.881 billion (-9.92% YoY), net profit attributable to shareholders of RMB 90 million (-68.53% YoY), and operating cash flow of RMB 34 million (-90.31% YoY) [1] - In Q2 2024, revenue was RMB 2.040 billion (-6.91% YoY), with net profit attributable to shareholders of RMB 108 million (-19.92% YoY) and operating cash flow of RMB 173 million (+28.99% YoY) [1] - The company's gross margin in Q2 2024 improved to 37.17%, up 5.08 percentage points QoQ [1] - Excluding the impact of credit impairment provisions, the company's net operating profit margin in Q2 2024 was 11.84% [1] Technological Innovation and Digital Transformation - The company launched 92 new projects in H1 2024, covering key disease areas such as kidney, infection, neurology, hematology, and endocrinology [2] - The company has developed a medical testing industry large model application called "Xiao Yu Yi" and is actively exploring the construction of a medical testing data element infrastructure [2] - The company has automated access and cleaning of medical testing data, with a total volume exceeding 23PB, including over 12PB of gene sequencing results [2] Financial Forecasts - The report forecasts the company's revenue for 2024-2026 to be RMB 8.134 billion, RMB 9.293 billion, and RMB 10.503 billion, respectively [7] - Net profit attributable to shareholders is expected to be RMB 609.69 million, RMB 905 million, and RMB 1.209 billion for 2024-2026, respectively [7] - EPS for 2024-2026 is projected to be RMB 1.30, RMB 1.93, and RMB 2.58, respectively [7] - The current stock price corresponds to a PE ratio of 21x, 14x, and 10x for 2024-2026 [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The core business of the company is stable and shows positive growth, driven by innovation and high-quality development results [1] - The company has reported a decline in revenue and net profit for the first half of 2024, attributed to external factors such as medical regulations and market competition [2][4] - Despite short-term challenges, the company is expected to benefit from long-term reforms in the healthcare system, which may enhance the willingness of hospitals to outsource testing services [1][2] Summary by Relevant Sections Financial Performance - In the first half of 2024, the company achieved operating revenue of 38.81 billion yuan, a year-on-year decrease of 9.92% [2] - The net profit attributable to shareholders was 0.90 billion yuan, down 68.53% year-on-year, while the net profit after deducting non-recurring items was 0.74 billion yuan, a decrease of 72.76% [2] - The company’s revenue for 2023 is projected to be 8.54 billion yuan, with a decline expected in 2024 and 2025 [2][9] Business Segments - The company’s core medical testing business remains stable, with significant growth in innovative specialty testing products [1] - The company has seen a 182% increase in revenue from its infection testing segment and a 234% increase in its high-end medical testing services [2][4] - The proportion of high-end technology platform business has increased by 5.81 percentage points year-on-year, indicating a shift towards more advanced medical testing solutions [2] Market Position and Strategy - The company is positioned as a leading player in the third-party medical testing service industry, maintaining relative stability in its overall performance despite external pressures [1][2] - The company is actively pursuing digital transformation and integrating artificial intelligence into its medical testing services, enhancing service quality and efficiency [1][2] - The company has established partnerships with various healthcare institutions, expanding its reach and service capabilities [1][2]

| --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | 证券研究报告 | | | 公司研究 | | | [Table_ReportType] 公司点评报告 | | | [Table_StockAndRank] 金域医学 (603882) | | | 投资评级 | | | | | | 上次评级 | | | | | | [Table_Author] 唐爱金 医药行业首席分析师 执业编号： S1500523080002 邮 箱： tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号： S1500523080011 邮 箱： caojialin@cindasc.com | | | 相关研究 | | | [Table_OtherReport] ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 1.2 billion RMB, representing a year-on-year growth of 15%[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2024, representing a year-over-year growth of 15%[10]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2024, representing a 20% year-over-year growth[68]. - The company has set a revenue guidance of 2.5 billion RMB for the full year 2024, which would represent a 10% increase from the previous year[19]. - The company has set a revenue guidance of 3 billion yuan for the full year 2024, projecting a growth rate of 25%[64]. - The company's operating revenue for the first half of the year was ¥3,880,906,151.11, a decrease of 9.92% compared to the same period last year[20]. - Net profit attributable to shareholders was ¥89,650,203.48, down 68.53% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥74,249,430.17, a decline of 72.76%[21]. - The net profit for the first half of 2024 was CNY 83,261,928.89, a decline of 70.5% compared to CNY 282,235,598.93 in the first half of 2023[96]. - The net profit for the first half of 2024 is approximately ¥416.1 million, a significant decrease of 76.9% compared to ¥1.8 billion in the same period of 2023[99]. User Engagement and Market Expansion - User data showed an increase in the number of tests conducted, reaching 5 million tests in the first half of 2024, up 20% compared to the same period last year[6]. - User data indicates that the number of tests conducted increased by 20% compared to the previous year, reaching 5 million tests in the first half of 2024[10]. - User data indicates that the active user base has expanded to 10 million, marking a 15% increase compared to the previous year[63]. - The company is expanding its market presence, with plans to open 10 new testing centers across major cities in China by the end of 2024[6]. - Market expansion efforts include opening 15 new testing centers across various provinces, projected to increase market share by 5%[10]. - The company is actively pursuing market expansion strategies, targeting an increase in market share by 10% in the next fiscal year[66]. - The company is expanding its market presence by opening 15 new laboratories across key regions in China, aiming to enhance service accessibility[19]. - The company is considering strategic acquisitions to enhance its service portfolio, with a budget of up to 500 million RMB allocated for potential deals[68]. Product Development and Innovation - New product launches include advanced diagnostic tools expected to enhance testing efficiency by 30%[6]. - New product launches in the diagnostics segment are anticipated to contribute an additional 200 million RMB in revenue by the end of 2024[10]. - New product launches include advanced genomic testing services, which are expected to contribute an additional 200 million RMB in revenue by the end of 2024[19]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing testing accuracy and efficiency[10]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing service efficiency and accuracy[68]. - The company launched several new products, including targeted sequencing for bloodstream infections and genetic testing for epilepsy, enhancing its product competitiveness[31]. - The company is actively integrating AI technology into its medical testing services, improving operational efficiency and service quality[27]. Operational Efficiency and Cost Management - The company has implemented new strategies to enhance operational efficiency, aiming to reduce costs by 5% in the next fiscal year[6]. - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management and operational efficiencies[10]. - The company has implemented a new logistics system to ensure the integrity of medical samples, which is expected to reduce operational costs by 15%[19]. - The company has implemented a digital management platform to enhance operational efficiency across its laboratories[31]. Customer Satisfaction and Quality Assurance - The management emphasized the importance of maintaining high-quality standards, with a 98% customer satisfaction rate reported[6]. - The overall customer satisfaction rate has increased to 90%, indicating strong service performance and client retention[10]. - The company has implemented a new quality assurance program, achieving ISO15189 accreditation for all major laboratories, enhancing credibility in the market[10]. - The company has established a comprehensive quality management system, recognized in over 70 countries, maintaining industry leadership for 22 consecutive years in certification and recognition[28]. Research and Development - Investment in research and development has increased by 25%, focusing on innovative medical technologies[6]. - Investment in research and development has increased by 25%, focusing on innovative diagnostic technologies and AI applications in healthcare[19]. - Research and development expenses were CNY 196,771,885.67, down 22.5% from CNY 254,207,470.53 in the previous year[96]. - The company published 54 papers and led or participated in the formulation of 8 standards during the reporting period, showcasing its commitment to innovation[31]. Regulatory and Compliance - The company is responding to stricter regulatory measures in the medical field to promote long-term healthy development[26]. - The company has a risk of delayed receivables, which may lead to funding risks due to increased collection days[44]. - The company faces policy risks that may lead to increased competition and price reductions in the medical testing industry[44]. Sustainability and Corporate Social Responsibility - A commitment to sustainability has been established, aiming to reduce operational carbon emissions by 20% over the next three years[64]. - The company has implemented a green laboratory initiative to reduce resource waste and pollution during the production process[57]. - The company has actively engaged in public welfare activities, covering 16 provinces to provide health screening services to economically disadvantaged patients[59]. - The company has established a wastewater treatment system that operates continuously, ensuring compliance with environmental standards[54]. Shareholder and Governance - The company has implemented a stock option incentive plan, granting 7 million stock options to 157 individuals as of September 8, 2020[50]. - The board of directors has approved a long-term incentive plan to align management interests with shareholder value, effective immediately[66]. - The company held its first extraordinary general meeting on January 31, 2024, to approve several governance proposals[46]. - The company has appointed two new independent directors, Fan Xia and Xie Huobao, to the board as of January 31, 2024[48]. Taxation and Financial Strategy - The corporate income tax rate for the company is set at 15% for the year 2024 due to its qualification as a high-tech enterprise[185]. - The company has a structured tax strategy that includes various tax rates for different services, ensuring compliance and optimization[182]. - The company is actively managing its tax obligations through strategic certifications and compliance with local tax regulations[186]. - The company has extended the loss carryforward period for high-tech enterprises from 5 years to 10 years, allowing for greater tax relief[191].